Want to see MESO full AI Analyst Report?
MESO Stock Chart & Stats
$16.46
-$0.53(-2.96%)
At close: 4:00 PM EST
$16.46
-$0.53(-2.96%)
Day’s Range― - ―
52-Week Range$10.32 - $21.50
Previous CloseN/A
Volume155.35K
Average Volume (3M)163.17K
Market Cap
$1.74B
Enterprise Value$1.91B
Total Cash (Recent Filing)$161.16M
Total Debt (Recent Filing)$128.16M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Sep 02, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding129,156,280
10 Day Avg. Volume150,514
30 Day Avg. Volume163,171
Financial Highlights & Ratios
PEG Ratio2.45
Price to Book (P/B)2.20
Price to Sales (P/S)76.48
P/FCF Ratio-25.95
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue110.93
Enterprise Value/Gross Profit-53.20
Enterprise Value/Ebitda-32.79
Forecast
1Y Price Target
$35.00Price Target Upside112.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)$199.80M
Bulls Say, Bears Say
Bulls Say
High‑margin Ryoncil Commercial TractionRyoncil's very high 93% gross margin and meaningful H1 revenues indicate scalable product economics. Durable margins support reinvestment into commercial expansion and R&D, improving the company's ability to fund trials and operations without eroding unit economics as volumes scale.
Strong Liquidity And Flexible FinancingA healthy cash balance plus an available credit tranche materially extends runway through near‑term regulatory and commercial milestones. This liquidity reduces immediate dilution risk, supports manufacturing scale‑up and trial execution, and provides flexibility to navigate milestone timing.
Advancing Regulatory Filings And Expedited DesignationsReceiving a BLA filing number and leveraging orphan/RMAT pathways creates a structural acceleration of the regulatory timeline. A modular review and priority pathways reduce regulatory execution risk and could materially shorten time to market and revenue maturation for rexlemestrocel‑L.
Bears Say
Persistent Operating Losses And Negative Cash FlowContinued half‑year losses and negative operating cash flow demonstrate the company is not yet self‑funding. Persistent cash burn increases reliance on external financing or milestone receipts, constraining flexibility and raising execution risk if commercial growth or financing access lags expectations.
High Revenue Concentration On Single ProductNearly all current revenue derives from one newly launched product, creating concentration risk. Any reimbursement, supply, or adoption setbacks would disproportionately harm cash flow and growth, since other pipeline programs remain years from potential commercialization.
Rising R&D And SG&A From Commercialization And TrialsMaterial increases in R&D and SG&A as the company scales commercialization and advances multiple late‑stage programs elevate burn and pressure margins. Higher fixed operating costs require sustained revenue growth to achieve profitability and extend the cash runway.
Mesoblast News
MESO FAQ
What was Mesoblast’s price range in the past 12 months?
Mesoblast lowest stock price was $10.32 and its highest was $21.50 in the past 12 months.
What is Mesoblast’s market cap?
Mesoblast’s market cap is $1.74B.
When is Mesoblast’s upcoming earnings report date?
Mesoblast’s upcoming earnings report date is Sep 02, 2026 which is in 62 days.
How were Mesoblast’s earnings last quarter?
Mesoblast released its earnings results on Feb 25, 2026. The company reported -$0.311 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.241.
Is Mesoblast overvalued?
According to Wall Street analysts Mesoblast’s price is currently Undervalued.
Does Mesoblast pay dividends?
Mesoblast does not currently pay dividends.
What is Mesoblast’s EPS estimate?
Mesoblast’s EPS estimate is 0.
How many shares outstanding does Mesoblast have?
Mesoblast has 129,156,280 shares outstanding.
What happened to Mesoblast’s price movement after its last earnings report?
Mesoblast reported an EPS of -$0.311 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went up 0.059%.
Which hedge fund is a major shareholder of Mesoblast?
Currently, no hedge funds are holding shares in MESO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (112.64% Upside)
$35.00 (112.64% Upside)
Blogger Sentiment
Bullish
MESO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $37.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.63%
12-Months-Change
Fundamentals
Return on Equity
-14.02%
Trailing 12-Months
Asset Growth
19.74%
Trailing 12-Months
Company Description
Mesoblast
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
MESO Company Deck
MESO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed strong commercial momentum following the successful Ryoncil launch (USD 49M H1 revenue, 93% gross margin), meaningful market access achievements (coverage for >280M lives, J-code, centers onboarded), robust cash and financing flexibility (USD 130M cash and new USD 125M facility), and compelling randomized data for Revascor and progress on rexlemestrocel-L. Offsetting these positives are sharp increases in R&D and SG&A as the company scales commercialization and advances clinical programs, continued operating losses and notable dependency on a single launched product while other programs mature. Overall, the call emphasized execution progress, regulatory engagement, and a clear path for near-term milestones, with manageable financial and execution risks.View all MESO earnings summariesMESO Stock 12 Month Forecast
Average Price Target
$35.00
▲(112.64% Upside)
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Adaptive Biotechnologies
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
26.26% Insiders
<0.01% Mutual Funds
0.25% Other Institutional Investors
73.03% Public Companies and
Individual Investors